Iowanews Headlines

Real-World Evidence (RWE) Solutions Market

Valued at USD 2,832.33 million in 2024, the market is projected to reach USD 5,240.07 million by 2032.

The growth of the RWE solutions market is driven by the rising prevalence of chronic diseases and the increasing use of real-world data to evaluate their impact. Technological advancements in big data analytics, artificial intelligence, and machine learning are enhancing the efficiency of data collection, processing, and analysis. Additionally, pharmaceutical and biotechnology companies are increasingly leveraging RWE solutions to accelerate drug development, support regulatory submissions, improve market access, and monitor post-market performance. These factors collectively contribute to the strong market expansion anticipated over the forecast period.

DelveInsight’s Real-World Evidence Solutions Market Insights report offers comprehensive coverage of current and forecast market trends, key growth drivers and challenges, market barriers, and competitive landscape, including individual company market shares and profiles of major players.

Request for a sample page report @ https://www.delveinsight.com/report-store/real-world-evidence-solution-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the Real World Evidence Solution Market Report

The Real-World Evidence (RWE) Solutions Market is expected to witness steady growth at a moderate CAGR between 2025 and 2032. According to DelveInsight’s estimates, North America is likely to remain the leading region in the global RWE solutions market throughout the forecast period.

Several major players are actively shaping the market landscape, including IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, and Cegedim Health Data, among others.

Key recent developments include:

• Datavant announced it signed an agreement to acquire Aetion, a leading RWE platform, in May 2025.

• April 2024: Flatiron Health extended its partnership with the National Comprehensive Cancer Network® (NCCN®) to continue maintaining the NCCN Quality & Outcomes Database, a cloud-based system collecting data from NCCN member institutions.

• September 2023: Accenture supported the Mount Sinai Health System in migrating its Epic EMR system to Microsoft Azure, marking the largest Epic deployment on Azure to date. The initiative, launched in 2022 with Avanade and Microsoft, aims to foster healthcare innovation and enhance care delivery.

• August 2023: Thermo Fisher Scientific Inc. completed its $912.5 million acquisition of CorEvitas, LLC, a provider of regulatory-grade real-world evidence for medical treatments, from Audax Private Equity, following its initial announcement in July 2023.

To read more about the latest highlights related to the Real World Evidence Solution market, get a snapshot of the key highlights entailed in the Global Real World Evidence Solution Market Report

Real World Evidence Solution Overview

Real-world evidence (RWE) solutions utilize data derived from sources outside traditional clinical trials—such as electronic health records (EHRs), insurance claims, patient registries, and wearable devices—to provide valuable insights into treatment effectiveness, safety, and patient outcomes across varied populations. These solutions are instrumental in informing healthcare decisions, supporting regulatory submissions, enhancing clinical trial design, and advancing patient-centric care.

Market growth is being propelled by factors such as the increasing burden of chronic diseases, the rising complexity of therapeutic pathways, and the widespread integration of advanced technologies like artificial intelligence (AI), machine learning (ML), and big data analytics to manage and interpret large-scale healthcare data more effectively. Additionally, strategic mergers, acquisitions, and partnerships among leading industry players are improving data accessibility and quality, thereby driving innovation in drug development, post-market surveillance, and value-based healthcare models.

As global healthcare systems increasingly prioritize better outcomes, cost efficiency, and personalized treatment approaches, RWE solutions are emerging as indispensable assets for stakeholders across the pharmaceutical, biotechnology, and clinical research domains.

Real World Evidence Solution Market Insights

North America is expected to account for the largest share of the real-world evidence (RWE) solutions market in 2024 among all regions. This leadership is attributed to the growing number of clinical trials driven by the rising prevalence of chronic diseases and the rapid adoption of advanced technologies such as artificial intelligence (AI), machine learning (ML), and data analytics, which improve the management and interpretation of extensive healthcare datasets. These innovations enable deeper insights into treatment effectiveness and patient outcomes. Furthermore, the strong presence of major pharmaceutical and biotechnology companies, along with robust R&D activities in drug discovery and development, continues to strengthen the region’s market position.

According to the International Agency for Research on Cancer (2024), North America recorded approximately 2.67 million new cancer cases in 2022, a number projected to rise to 3.83 million by 2045. In Canada, cancer incidence is expected to grow from 292,000 cases in 2022 to 449,000 by 2045. This escalating cancer burden highlights the urgent need for comprehensive RWE solutions, which provide crucial insights into treatment efficacy, support regulatory decision-making, optimize healthcare resource utilization, enhance safety monitoring, and foster patient-centric care. The expanding use of RWE in oncology research and clinical practice is anticipated to significantly propel market growth, advance therapeutic innovation, and improve outcomes for both patients and healthcare systems across the region.

To know more about why North America is leading the market growth in the Real World Evidence Solution market, get a snapshot of the Real World Evidence Solution Market Outlook

Real World Evidence Solution Market Dynamics

According to the Global Cancer Observatory (2024), there were approximately 20 million new cancer cases worldwide in 2022, a figure expected to surge to 32.6 million by 2045. In Europe, cancer incidence stood at around 4.47 million cases in 2022 and is projected to reach 5.48 million by 2045. As cancer cases continue to rise, real-world evidence (RWE) solutions are increasingly being adopted in oncology to guide clinical decision-making and reimbursement strategies, particularly in light of the wide variation in patient populations and treatment modalities. By utilizing data from electronic health records (EHRs), payer claims, patient registries, and other sources, RWE enables a deeper understanding of treatment performance, outcomes, and disease trends across large, heterogeneous populations. This growing need for actionable insights to enhance cancer management and patient care is fueling the demand for RWE solutions globally.

Moreover, pharmaceutical and biotechnology companies are increasingly leveraging RWE to accelerate drug development and facilitate market access. Compared with randomized clinical trials (RCTs)—which are often costly, time-consuming, and limited in scope—RWE helps identify target patient groups, refine trial criteria, and optimize study designs, resulting in faster recruitment, lower costs, and improved trial success rates. For instance, in August 2021, the diabetes drug Jardiance (empagliflozin) was approved for a new indication based partly on real-world evidence showing its efficacy in reducing cardiovascular events among heart failure patients, including those without diabetes, thereby complementing data from the EMPEROR-Reduced Phase III trial.

By providing a comprehensive view of treatment effectiveness in real-world settings, RWE strengthens therapy validation, enhances patient outcomes, and stimulates innovation across the healthcare ecosystem—driving steady expansion of the global RWE market. However, challenges related to data validation, operational integration, and information security remain key factors that could modestly limit market growth.

Real World Evidence Solution Market Drivers:

• Increasing prevalence of chronic diseases

• Growing technological advancement

• Increasing application of real-world evidence solutions in pharmaceutical and biotechnology industries across the globe

Get a sneak peek at the Real World Evidence Solution market dynamics @ https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Scope of the Real World Evidence Solution Market Report:

• Coverage: Global

• Study Period: 2022 to 2032

• Key Real World Evidence Solution Companies: IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, Cegedim Health Data, and others.

Which MedTech key players in the Real World Evidence Solution market are set to emerge as the trendsetter, explore @ Real World Evidence Solution Companies

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/